GR99060 and GR99062 are representatives of a series of 1,2,4-triazino [5,6-b]indole compounds. This series possessed broad-spectrum antifungal activity in vitro. The MIC ranges of the two compounds were as follows: 0.25 to 4 ,ug/ml for Candida albicans, 0.25 to 16 ,ug/ml for Candida sp., 1 to 8 ,ug/ml for Asperigllus spp., and 0.25 to 16 ,ug/ml for Cryptococcus neoformans. GR99062 was metabolized in vitro by a mouse liver microsomal preparation, while GR99060 was stable. GR99060 was efficacious in a murine model of systemic candidiasis by oral or parenteral administration, although no clear dose-response was achieved, suggesting that other factors adversely affected the compound's in vivo activity.
As a result of an ongoing random screening program, antifungal activity was detected in a series of 1,2,4-triazino [5,6-b] indoles. A group of 3-substituted triazinoindoles has been reported to have antiviral activity (2, 3, 5, 6-8, 10, 12) . Activity against Aspergillus niger was described in one report (1) in which compounds inhibited growth in vitro and also reduced infection of sorghum seeds. In the present report we describe the biological properties of two novel triazinoindoles.
MATERIALS AND METHODS
Compounds. GR99060, GR99062, and GR10767 were synthesized at Glaxo Group Research (Fig. 1) . Amphotericin B was obtained from Sigma. Ketoconazole was purchased from Janssen Pharmaceuticals.
In vitro antifumgal activity. The fungi used in the present study were obtained from the Glaxo Culture Collection (see Table 1 ) and were previously isolated from clinical infections. The yeast isolates were identified by using the AP 120C system (API Ltd.), and the Aspergillus spp. were identified by their colonial morphologies and microscopic identification. MICs were determined by the agar dilution method with Iso-Sensitest agar (pH 7.4; Oxoid Ltd.). Fungi were applied to the surface of the agar with a multipoint inoculator (Denley Ltd.), which delivered 10 ,ul of 107 condia per ml for Aspergillus spp., 107 CFU/ml for Cryptococcus neoformans, and 105 CFU/ml for all other yeasts. All cultures were incubated at 37°C for 18 h except for Aspergillus spp. and C. neoformans cultures, which were incubated for 48 h. To determine fungicidal or fungistatic inhibition, Candida albicans C316 was inoculated into Iso-Sensitest broth at 5 x 10' CFU/ml, with compounds used at a concentration range of 100 to 0.1 ,ug/ml, and the mixture was incubated with shaking at 37°C. Four 25-,ul samples were plated onto Iso-Sensitest agar at 2, 4, 6, and 24 h, and the plates were incubated for 18 h at 37°C.
In vitro metabolism. Compounds at 10 ,ug/ml were incubated with a mouse liver microsomal preparation obtained from a liver homogenate made up of the supematant obtained after centrifugation at 9,000 x g (4). Cofactors containing 5 mM glucose 6- With a flow rate of 1 ml/min the retention time was 3.25 min. The area under the curve of the compound peak was integrated. For GR99060, the assay conditions were similar to those for GR99062, except the proportion of acetonitrile to buffer was 40:60 and the retention time was 5.45 min.
Pharmacokinetics. The compounds were suspended in 0.5% sodium carboxymethyl cellulose in saline and administered to female CRH mice by the oral, subcutaneous, or intraperitoneal route at a dosage of 50 mg/kg of body weight. At 0.5, 1, 2, and 4 h after dosing, mice were humanely killed and blood samples were obtained by heart puncture. The sera from three mice were pooled at each time point. The concentration of compound in the pooled sample was detected by HPLC as described above. In mice dosed with GR99060, the area around the subcutaneous site of injection was removed and extracted with dimethyl sulfoxide, and the concentration of compound was measured by HPLC.
In vivo efficacy. C. albicans C316 was inoculated into 100 ml of Sabouraud dextrose broth (Oxoid), and the mixture was incubated overnight at 37°C. Following centrifugation at 10,000 x g the organisms were resuspended and diluted in fresh broth. Acute systemic murine candidiasis was achieved following an intraperitoneal challenge of 2 x 107 C. albicans C316 blastospores with 1% YESTAMIN (baker's yeast). Therapy was given at 1, 3, and 5 h postinfection; the doses ranged from 100 to 0.3 mg/kg per dose. Each group contained 10 or 15 mice. The number of survivors was determined after 5 days. For measurement of the growth of C. albicans in the kidneys of mice, a sublethal challenge of 8 x 105 C albicans C316 blastospores was given intravenously. Doses were then administered to the mice twice a day on the day of challenge and two subsequent days. On the third day the mice were killed, their kidneys were removed and homogenized in pairs, and the Candida load was quan-KINSMAN ET AL. to mice. Oral absorption was good; however, the concentrations obtained in serum after subcutaneous dosing were very low, and precipitation of the compound at the injection site was noted ( Table 2 ). The compound was not excreted in the urine. In vivo efficacy. GR99060 showed a therapeutic effect in mice with acute systemic C. albicans infections, but the dose-response was variable (Table 3) . Fewer mice survived after receiving 3 doses of 100 mg/kg than after receiving 3 doses of 25 mg/kg. This may have been due to toxicity experienced with the 100-mg/kg dose in infected animals, although no deaths or signs of toxicity were seen in uninfected animals with a similar dosing schedule (i.e., five of five uninfected mice survived the 100-and 25-mg/kg doses). Protection was seen after subcutaneous and oral dosing, despite the very low levels in serum when the compound was given by the subcutaneous route. Ketoconazole was effective when it was administered by both routes and gave a dose-response (50% effective dose by the oral route, 7.3 mg/kg/dose; 50% effective dose by the subcutaneous route, 3.2 mg/kg/dose).
Attempts to increase the efficacy with altered dosing schedules did not improve the rate of survival. To investigate the potential efficacy of the drugs in mice with less acute infections, a model was developed with a sublethal challenge of C albicans in the kidneys, which allowed for dosing over a longer time period. GR99060 reduced the growth of C. albicans in the kidneys, but only with 100 mg/kg adminis- tered orally (P < 0.05) (Fig. 4) . Ketoconazole reduced the growth of C albicans when it was administered at 20 mg/kg/dose (given orally) and 40 mg/kg/dose (given subcutaneously) (data not shown). DISCUSSION GR99060 and GR99062 are representatives of a series of novel triazinoindole compounds that possess broad-spectrum antifungal activity in vitro. Except for Candida tropicalis, good activity against a wide variety of Candida spp., Aspergillus spp. and C. neoformans was noted. Triazinoindoles have been described to have activity against A. niger, and when provided as seed dressing, they protected sorghum seeds from infection with this organism (1) . The modes of action of these drugs are not known. Some triazinoindoles have antiviral properties. SK&F 30097 was active against picornavirus in vitro and RNA synthesis was inhibited (7), while SK&F 21681 had activity against herpes simplex virus, in which DNA synthesis was suppressed (8) . Triazinoindoles which were structurally less closely related to the triazinoindoles examined in the present study were also shown to have antihypertensive properties (11) and inhibit thromboxane synthetase in rats. Some triazinoindoles are also mutagenic (9) . Thus, the description of the antifungal activities of triazinoindole compounds against human pathogens is new, and no mode of action is suggested from the literature.
Metabolic instability was a common problem in the present study. N-oxidation occurred with GR99062 in vitro and in vivo. A prescreen for metabolic stability in vitro was a useful predictor of metabolic stability in vivo and, thus, the potential for efficacy. GR99060 showed a therapeutic effect in mice with systemic C. albicans infections when it was administered by both the oral and subcutaneous routes. Since the levels of the drug in blood after subcutaneous dosing were low, the compound may be released slowly over a longer period of time. In the efficacy test, the dose-response was variable by both routes. Toxicity in infected animals may account for the reduced activity at high doses, since a lower survival rate was noted in mice that received 100 mg/kg than in those that received lower doses. Variations in bioavailability and possible further metabolism may also account for the lack of good dose-responses. Similarly, in the subacute infection model, the oral route of administration was more effective than the subcutaneous route in reducing kidney counts when a dose of 100 mg/kg was used.
Attempts to improve the pharmacokinetics of GR99060 should result in a more consistent antifungal effect in vivo, although consideration must be given to potential side effects, e.g., hypotension.
